LP145572-6
Epstein Barr virus capsid Ab.IgG avidity
Active
Description
Avidity testing of Epstein Barr virus (EBV) capsid IgG is performed to differeniate between a primary and past infection. When B cells switch from the IgM to the IgG isotype in vivo, the first IgG antibodies produced are of low avidity. As IgG antibodies mature, B-cells end up producing IgG antibodies of relative higher avidities or binding strengths compared to early IgG antibodies. The IgG maturation process is usually completed within a few weeks after primary EBV infection. Measurements are obtained by EIA and a ratio is calculated between a patient's urea-treated and non-urea-treated samples to define the avidity index. PMID: 15297472 Source: Regenstrief LOINC, PMID: 15297472
Basic Part Properties
- Part Display Name
- Epstein Barr virus capsid IgG avidity
- Part Type
- Component (Describes the core component or analyte measured)
- Created On
- 2012-01-02
- Construct for LOINC Short Name
- EBV IgG Avidity
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=LP145572-6
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| pl-PL | Polish (Poland) | Wirus Epsteina Barr antygen kapsydowy Ab.IgG awidność Synonyms: Awidność przeciwciał IgG do antygenu kaspydowego wirusa Epsteina-Barr |
LOINC Copyright
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright